Immunitybio, INC 8-K filings

ImmunityBio announced record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year, alongside significant progress in its clinical pipeline and regulatory milestones.

ImmunityBio announced that the UAE has granted marketing authorization for ANKTIVA in two indications: BCG-unresponsive bladder cancer and metastatic non-small cell lung cancer.

ImmunityBio, Inc. successfully held its 2026 Annual Meeting of Stockholders, confirming the re-election of all nine director nominees and the ratification of its independent auditor.

ImmunityBio has entered an exclusive agreement with Japan BCG Laboratory to develop and commercialize the Tokyo-172 BCG strain in the U.S. to address chronic supply shortages.

ImmunityBio announced record Q1 2026 results with net product revenue soaring to $44.2 million, a nearly 2.7x increase year-over-year, driven by strong ANKTIVA sales and expanding market approvals.

ImmunityBio announced preliminary Q1 2026 net product revenue of approximately $44.2 million, a 168% increase year-over-year, driven by ANKTIVA adoption.

ImmunityBio has submitted a formal response to an FDA warning letter regarding promotional materials for its therapy ANKTIVA.

ImmunityBio strengthens its balance sheet with $75 million in non-dilutive financing and a $25 million debt-to-equity conversion by an affiliated entity, supporting global expansion and pipeline advancement.

ImmunityBio announced a 700% year-over-year revenue increase for ANKTIVA, expanded global regulatory approvals, and its first lung cancer authorization, signaling strong commercial momentum.

ImmunityBio, Inc. has amended a $505 million convertible promissory note held by Nant Capital, LLC, allowing for partial conversion into common stock.

ImmunityBio, Inc. announced preliminary Q4 and full-year 2025 financial results, highlighting a 700% year-over-year increase in ANKTIVA net product revenue and new global approvals.

ImmunityBio announced accelerated approval from the Saudi Food and Drug Authority for its immunotherapy ANKTIVA for both metastatic non-small cell lung cancer and BCG-unresponsive non-muscle invasive bladder cancer.

ImmunityBio, Inc. amended its Open Market Sale Agreement to allow for the sale of an additional $459.97 million in common stock and increased its authorized common stock to 1.65 billion shares.

ImmunityBio, Inc. announced the appointment of Bruce Wendel, a seasoned pharmaceutical executive, to its Board of Directors, effective December 12, 2025.

ImmunityBio's ANKTIVA, combined with BCG, received a conditional marketing authorization recommendation from the European Medicines Agency for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ.

ImmunityBio reported significant year-to-date unit growth and sales for ANKTIVA, alongside promising clinical trial results for various cancer indications and a strengthened cash position.

ImmunityBio, Inc. has reached a proposed settlement in consolidated shareholder derivative actions, agreeing to implement significant corporate governance reforms.

ImmunityBio reported a 60% increase in Q2 2025 revenue driven by strong ANKTIVA sales, alongside progress in clinical trials and a recent equity financing.

ImmunityBio announced an $80 million registered direct offering, reporting a 60% increase in Q2 2025 revenue and significant ANKTIVA sales growth, while navigating a Refuse-to-File decision from the FDA for its papillary NMIBC supplemental BLA.

ImmunityBio, Inc. announced that its stockholders overwhelmingly approved the 2025 Equity Incentive Plan and re-elected all eight director nominees at its Annual Meeting on June 18, 2025.

ImmunityBio announces a 129% increase in net product revenue and a 150% growth in ANKTIVA unit sales volume for Q1 2025, driven by the permanent J-code and expanded access program.

ImmunityBio's supplemental biologics license application (sBLA) for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for papillary disease has received a Refusal to File (RTF) letter from the FDA, despite prior guidance.

ImmunityBio reports FDA submissions for ANKTIVA in bladder cancer and lymphopenia, alongside a 129% increase in Q1 revenue.

ImmunityBio has entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $75 million before deducting any offering-related expenses, subject to customary closing conditions.

ImmunityBio announced the dismissal of Ernst & Young LLP and the appointment of Deloitte & Touche LLP as its new independent registered public accounting firm.

ImmunityBio reports significant sales momentum and unit growth for ANKTIVA following the issuance of a permanent J-code in January 2025, along with financial results for the year ended December 31, 2024.

ImmunityBio's Compensation Committee approves 2024 executive bonuses, establishes the 2025 Long-Term Incentive Program, and sets 2025 annual base salaries for its named executive officers.

John Owen Brennan resigned from ImmunityBio's Board of Directors and all committees, effective February 7, 2025.

ImmunityBio has successfully priced a public offering of common stock, raising approximately $100 million, and restructured a significant portion of its debt.

ImmunityBio plans a public offering of common stock and a debt restructuring involving the conversion of existing debt into equity and a new consolidated note.